Table 3.
Disease and treatment-related factors
| n | Statistic | |
| Neoadjuvant chemotherapy | 413 | |
| No | 69 (16.7) | |
| Yes | 344 (83.3) | |
| Mandard score | 387 | |
| Mandard 1 (Complete) | 20 (5.2) | |
| Mandard 2 | 26 (6.7) | |
| Mandard 3 | 69 (17.8) | |
| Mandard 4 | 115 (29.7) | |
| Mandard 5 (None) | 88 (22.7) | |
| No Chemo | 69 (17.8) | |
| Operation stages | 413 | |
| Two-stage | 379 (91.8) | |
| Three-stage | 34 (8.2) | |
| Operation type | 413 | |
| Hybrid | 224 (54.2) | |
| MIO | 103 (24.9) | |
| Open | 86 (20.8) | |
| Type of Tumour | 409 | |
| Adenocarcinoma | 322 (78.7) | |
| Adenosquamous | 8 (2.0) | |
| Squamous | 65 (15.9) | |
| Other | 14 (3.4) | |
| T-stage | 410 | |
| T0 | 17 (4.1) | |
| T1 | 43 (10.5) | |
| T2 | 51 (12.4) | |
| T3 | 274 (66.8) | |
| T4 | 25 (6.1) | |
| N-stage | 412 | |
| N0 | 154 (37.4) | |
| N1 | 171 (41.5) | |
| N2 | 54 (13.1) | |
| N3 | 33 (8.0) | |
| M-stage | 405 | |
| M0 | 396 (97.8) | |
| M1 | 9 (2.2) | |
| R-status | 407 | |
| R0 | 255 (62.7) | |
| R1 | 141 (34.6) | |
| R2 | 11 (2.7) | |
| Peri-neural invasion | 314 | |
| No | 207 (65.9) | |
| Yes | 107 (34.1) | |
| Lymph nodes total | 412 | 30.3 ± 10.8 |
| Lymph nodes involved | 412 | 1 (0-4) |
Data are reported as n (%), mean ± SD, or as median (IQR), as applicable. Mandard Score is a measure of tumour regression due to chemotherapy, with a score of 1 being complete regression, and 5 being no regression. MIO: Minimally invasive oesophagectomies.